Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis

Diabetes Research and Clinical Practice

Volumn 105, Issue 1, 2014, Pages 47-57

  Jung, Yun A ^a   Choi, Yeon Kyung ^b   Jung, Gwon Soo ^b   Seo, Hye Young ^a   Kim, Hye Soon ^a   Jang, Byoung Kuk ^a   Kim, Jung Guk ^b   Lee, In Kyu ^b   Kim, Mi Kyung ^a   Park, Keun Gyu ^b  

^a Keimyung University School of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

DPP 4 inhibitor; GLP 1; MCD diet; Non alcoholic steatohepatitis (NASH); Sitagliptin

Indexed keywords

CYTOCHROME P450 2E1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SITAGLIPTIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CHOLINE; CYTOKINE; FIBRONECTIN; METHIONINE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; FATTY ACID TRANSPORT; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; LIPID STORAGE; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NICK END LABELING; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; BODY WEIGHT; C57BL 6 MOUSE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FATTY LIVER; GLUCOSE TOLERANCE TEST; INFLAMMATION; LIVER; NUTRITIONAL DEFICIENCY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

DPP-4 INHIBITOR; GLP-1; MCD DIET; NON-ALCOHOLIC STEATOHEPATITIS (NASH); SITAGLIPTIN;

ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CHOLINE DEFICIENCY; DIET; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; IMMUNOENZYME TECHNIQUES; INFLAMMATION; LIPID PEROXIDATION; LIVER CIRRHOSIS; MALE; METHIONINE; MICE; MICE, INBRED C57BL; NF-KAPPA B; PYRAZINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRIAZOLES; TRIGLYCERIDES;

EID: 84902540426     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.04.028     Document Type: Article

References (45)

1. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
2. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., Lok A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
4. Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37:909-916.
5. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
6. Chalasani N., Deeg M.A., Persohn S., Crabb D.W. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98:1849-1855.
7. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
8. Sanyal A.J., Chalasani N., Kowdley K.V., Mccullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
9. Ohnuma K., Takahashi N., Yamochi T., Hosono O., Dang N.H., Morimoto C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci 2008, 13:2299-2310.
10. Dobrian A.D., Ma Q., Lindsay J.W., Leone K.A., Ma K., Coben J., et al. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab 2011, 300:E410-E421.
11. Lenski M., Kazakov A., Marx N., Bohm M., Laufs U. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 2011, 51:906-918.
12. Panchapakesan U., Mather A., Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Sci (Lond, England: 1979) 2013, 124:17-26.
13. Firneisz G., Varga T., Lengyel G., Feher J., Ghyczy D., Wichmann B., et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PloS ONE 2010, 5:e12226.
14. Balaban Y.H., Korkusuz P., Simsek H., Gokcan H., Gedikoglu G., Pinar A., et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007, 6:242-250.
15. Loster K., Zeilinger K., Schuppan D., Reutter W. The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem Biophys Res Commun 1995, 217:341-348.
16. Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol Today 1994, 15:180-184.
17. Maiztegui B., Borelli M.I., Madrid V.G., Del Zotto H., Raschia M.A., Francini F., et al. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased beta-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond, England: 1979) 2011, 120:73-80.
18. Yilmaz Y., Yonal O., Deyneli O., Celikel C.A., Kalayci C., Duman D.G. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2012, 75:240-244.
19. Puri P., Mirshahi F., Cheung O., Natarajan R., Maher J.W., Kellum J.M., et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008, 134:568-576.
20. Rahman S.M., Schroeder-Gloeckler J.M., Janssen R.C., Jiang H., Qadri I., Maclean K.N., et al. CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology 2007, 45:1108-1117.
21. Rinella M.E., Green R.M. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004, 40:47-51.
22. Leclercq I.A., Farrell G.C., Field J., Bell D.R., Gonzalez F.J., Robertson G.R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000, 105:1067-1075.
23. Ip E., Farrell G.C., Robertson G., Hall P., Kirsch R., Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003, 38:123-132.
24. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351.
25. Miquilena-Colina M.E., Lima-Cabello E., Sanchez-Campos S., Garcia-Mediavilla M.V., Fernandez-Bermejo M., Lozano-Rodriguez T., et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 2011, 60:1394-1402.
26. Hajri T., Abumrad N.A. Fatty acid transport across membranes: relevance to nutrition and metabolic pathology. Annu Rev Nutr 2002, 22:383-415.
27. Koonen D.P., Jacobs R.L., Febbraio M., Young M.E., Soltys C.L., Ong H., et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 2007, 56:2863-2871.
28. Morimoto M., Zern M.A., Hagbjork A.L., Ingelman-Sundberg M., French S.W. Fish oil, alcohol, and liver pathology: role of cytochrome P450 2E1. Proc Soc Exp Biol Med 1994, 207:197-205.
29. Henkel A.S., Gooijert K.E., Havinga R., Boverhof R., Green R.M., Verkade H.J. Hepatic overexpression of Abcb11 in mice promotes the conservation of bile acids within the enterohepatic circulation. Am J Physiol Gastrointest Liver Physiol 2013, 304:G221-G226.
30. Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., Jiang G., et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003, 100:6825-6830.
31. Ding X., Saxena N.K., Lin S., Gupta N.A., Anania F.A. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006, 43:173-181.
32. Patankar J.V., Obrowsky S., Doddapattar P., Hoefler G., Battle M., Levak-Frank S., et al. Intestinal GATA4 deficiency protects from diet-induced hepatic steatosis. J Hepatol 2012, 57:1061-1068.
33. Ben-Shlomo S., Zvibel I., Shnell M., Shlomai A., Chepurko E., Halpern Z., et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 2011, 54:1214-1223.
34. Nakano H., Nagasaki H., Barama A., Boudjema K., Jaeck D., Kumada K., et al. The effects of N-acetylcysteine and anti-intercellular adhesion molecule-1 monoclonal antibody against ischemia-reperfusion injury of the rat steatotic liver produced by a choline-methionine-deficient diet. Hepatology 1997, 26:670-678.
35. Ansorge S., Nordhoff K., Bank U., Heimburg A., Julius H., Breyer D., et al. Novel aspects of cellular action of dipeptidyl peptidase IV/CD26. Biol Chem 2011, 392:153-168.
36. Fadini G.P., Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vasc Pharmacol 2011, 55:10-16.
37. Levy M.T., Mccaughan G.W., Abbott C.A., Park J.E., Cunningham A.M., Muller E., et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999, 29:1768-1778.
38. Mentzel S., Dijkman H.B., Van Son J.P., Koene R.A., Assmann K.J. Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J Histochem Cytochem 1996, 44:445-461.
39. Kirino Y., Sei M., Kawazoe K., Minakuchi K., Sato Y. Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. Endocr J 2012, 59:949-953.
40. Wang X.Y., Weng S.Y., Klein T., Kim Y.O., Schuppan D. Anti-inflammatory and direct antifibrotic effect of the oral hepatotropic DPP4 inhibitor Linagliptin in model of bilary fibrosis and NASH. Z Gastroenterol 2013, 51:K174.
41. Rinella M.E., Elias M.S., Smolak R.R., Fu T., Borensztajn J., Green R.M. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 2008, 49:1068-1076.
42. Rizki G., Arnaboldi L., Gabrielli B., Yan J., Lee G.S., Ng R.K., et al. Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. J Lipid Res 2006, 47:2280-2290.
43. Leclercq I.A., Lebrun V.A., Starkel P., Horsmans Y.J. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. Lab Invest 2007, 87:56-65.
44. Wu C.W., Chu E.S., Lam C.N., Cheng A.S., Lee C.W., Wong V.W., et al. PPARgamma is essential for protection against nonalcoholic steatohepatitis. Gene Ther 2010, 17:790-798.
45. Jiao P., Xu H. Adipose inflammation: cause or consequence of obesity-related insulin resistance. Diabetes Metab Syndr Obes 2008, 1:25-31.